Neues in der konservativen Therapie bei Arthrosen großer Gelenke

Nehrer S. Kniearthrose. Österr Ärztezeitung, 3: 28–38, 2007 Berenbaum F. Osteoarthritis – Epidemiology, Pathology, and Pathogenesis. In: Klippel JH, et al. (eds) Primer on the Rheumatic Diseases. 12th edn. Arthritis foundation, pp 285–289, 2001 Vuolteenaho K, Moilanen T, Knowles RG, Moilanen E. The role of nitric oxide in osteoarthritis. Scand J Rheumatol, 36: 247–258, 2007 Dodge GR, Jimenez SA. Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthritis Cartlilage, 11: 424–432, 2003 Iqbal I, Fleischmann R. Treatment of osteoarthritis with anakinra. Curr Rheumatol Rep, 9: 31–35, 2007 Blaney Davidson EN, van der Kraan PM, van den berg WB. TGF-beta and osteoarthritis. Osteoarthritis Cartilage, 15: 597–604, 2007 Bijlsma JW, Knahr K. Strategies for the prevention and management of osteoarthritis of the hip and knee. Best Pract Res Clin Rheumatol, 21: 59–76, 2007 O'Reilly S, Doherty M. Lifestyle changes in the management of osteoarthritis. Best Pract Res Clin Rheumatol, 15: 559–568, 2001 Bröll J, Kotz R. Konsensus Statement: Arthrose – Diagnostik und Therapie. Clinicum Sonderausgabe, pp 1–12, 2001 Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, Hauselmann HJ, Herrero-Beaumont G, Jordan K, Kaklamanis P, Leeb B, Lequesne M, Lohmander S, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Swoboda B, Varatojo R, Verbruggen G, Zimmermann-Gorska I, Dougados M. EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis, 64: 669–681, 2005 Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, Gunther K, Hauselmann H, Herrero-Beaumont G, Kaklamanis P, Lohmander S, Leeb B, Lequesne M, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Serni U, Swoboda B, Verbruggen G, Zimmerman-Gorska I, Dougados M. Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis, 62: 1145–1155, 2003 Felson DT, Zhang Y, Hannan MT, Naimark A, Weissman B, Aliabadi P, Levy D. Risk factors for incident radiographic knee osteoarthritis in the elderly – the framingham study. Arthritis Rheum, 40: 728–733, 1997 Cooper C, Snow S, McAlindon TE, Kellingray S, Stuart B, Coggon D, Dieppe PA. Risk factors for the incidence and progression of radiographic knee osteoarthritis. Arthritis Rheum, 43: 995–1000, 2000 Spector TD, Hart DJ, Doyle DV. Incidence and progression of osteoarthritis in women with unilateral knee disease in the general population: the effect of obesity. Ann Rheum Dis, 53: 565–568, 1994 Sharma L, Lou C, Cahue S, Dunlop DD. The mechanism of the effect of obesity in knee osteoarthritis. Arthritis Rheum, 43: 568–575, 2000 Felson DT, Goggins J, Niu J, Zhang Y, Hunter DJ. The effect of body weight on progression of knee osteoarthritis is dependent on alignment. Arthritis Rheum, 50: 3904–3909, 2004 Holmberg S, Thelin A, Thelin N. Knee osteoarthritis and body mass index: a population based case-control study. Scand J Rheumatol, 34: 59–64, 2005 Lievense AM, Bierma-Zeinstra SM, Verhagen AP, van Baar ME, Verhaar JA, Koes BW. Influence of obesity on the development of osteoarthritis of the hip: a systematic review. Rheumatology (Oxford), 41: 1155–1162, 2002 Reijman M, Pols HA, Bergink AP, Hazes JM, Belo JN, Lievense AM, Bierma-Zeinstra SM. Body mass index associated with onset and progression of osteoarthritis of the knee but not of the hip: the Rotterdam study. Ann Rheum Dis, 66: 158–162, 2007 Karlson EW, Mandl LA, Aweh GN, Sangha O, Liang MH, Grodstein F. Total hip replacement due to osteoarthritis: the importance of age, obesity, and other modifiable risk factors. Am J Med, 114: 93–98, 2003 Liu B, Balkwill A, Banks E, Cooper C, Green J, Beral V. Relationship of height, weight and body mass index to the risk of hip and knee replacement in middle-aged women. Rheumatology (Oxford), 46: 861–867, 2007 Messier SP, Gutekunst DJ, Davis C, DeVita P. Weight loss reduces knee-joint loads in overweight and obese older adults with knee osteoarthritis. AnnRheum Dis, 64: 2026–2032, 2005 Christensen R, Bartels EM, Astrup A, Bliddal H. Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis. Ann Rheum Dis, 66: 433–439, 2007 Felson DT, Zhang Y, Anthony JM, Naimark A, Anderson JJ. Weight loss reduces the risk of symptomatic knee osteoarthritis in women. The Framingham Study Ann Intern Med, 116: 535–539, 1992 Lohmander SL, Gerhardsson M, Rollof J, Nilsson PM, Engström G. Incidence of severer knee and hip osteoarthritis in relation to different measures of body mass. A population-based prospective cohort study. Ann Rheum Dis, 67, doi: 10.1136, 2008 Hayden JA, van Tulder MW, Malmivaara A, Koes BW. Exercise therapy for treatment of non-specific low back pain. Cochrane Database Syst Rev, CD000335. Review, 2005 Johnson M, Martinson M. Efficacy of electrical nerve stimulation for chronic musculoskeletal pain: a meta-analysis of randomized controlled trials. Pain, 130: 157–165, 2007 Pourkarami A, Keilani M, Sedghi-Komanadj T, Fialka-Moser V, Crevenna R. Ultraschalltherapie und Elektrotherapie bei muskuloskelettalen Erkrankungen. Phys Rehab Kur Med, 16: A63, 2006 Osiri M, Welch V, Brosseau L, Shea B, McGowan J, Tugwell P, Wells G. Transcutaneous electrical nerve stimulation for knee osteoarthritis. Cochrane Database Syst Rev, CD002823. Review, 2000 Taylor P, Hallett M, Flaherty L. Treatment of osteoarthritis of the knee with trancutaneous electrical nerve stimulation. Pain, 11: 233–240, 1981 McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase-2. JAMA, 296: 1633–1644, 2006 emea.europe.com. Annex II. Scientific conclusions and grounds for amendment of the summary of product characteristics presented by the EMEA. 2005 Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev, Jan 25 (1): 2006 Wolfe F, Zhao S, Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum, 43: 378–385, 2000 Chan FK, Wong VW, Suen BY, Wu JC, Ching JY, Hung LC, Hui AJ, Leung VK, Lee VW, Lai LH, Wong GL, Chow DK, To KF, Leung WK, Chiu PW, Lee YT, Lau JY, Chan HL, Ng EK, Sung JJ. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet, 369: 1621–1626, 2007 Leeb BF, Schweitzer H, Montag K, Smolen JS. A metaanalysis of chondroitin sulphate in the treatment of osteoarthritis. J Rheumatol, 27: 205–211, 2000 Michel BA, Stucki G, Frey D, De Vathaire F, Vignon E, Brühlmann P, Uebelhart D. Chondroitin 4 and 6 sulphate in osteoarthritis of the knee. Arthritis Rheum, 52: 779–786, 2005 Reichenbach S, Sterchi R, Scherer M, Trelle S, Bürgi E, Bürgi U, Dieppe PA, Jüni P. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med, 146: 580–590, 2007 Mazières B, Hucher M, Zaim M, Garnero P. Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicenter, randomized, double blind, Plazebo-controlled study. Ann Rheum Dis, 66: 639–645, 2007 Louthrenoo W, Nilganuwong S, Aksaranugraha S, Asavatanabodee P, Saengnipanthkul S, The Thai Study Group. The efficacy, safety, and carry-over effect of diacerein in the treatment of painful knee osteoarthritis: a randomized, double blind, NSAID-controlled study. Osteoarthritis Cartilage, 15: 605–614, 2007 Rintelen B, Neumann K, Leeb BF. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. Arch Intern Med, 166: 1899–1906, 2006 Fidelix TSA, Soares BGDO, Trevisani VFM. Diacerhein for osteoarthritis. Cochrane Database Syst Rev. Issue 1, 2006 Mc Alindon TE, La Valley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA, 283: 1469–1474, 2000 Mc Alindon T, Formica M, La Valley M, et al. Effectiveness of glucosamine for symptoms of knee osteoarthritis:results from an internet-based randomized double blind controlled trial. Am J Med, 117: 643–650, 2004 Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, Plazebo-controlled, double-blind study. Arch Intern Med, 162: 2113–2123, 2002 Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE, Gossett C. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomized Plazebo controlled clinical trial. Lancet, 357: 251–256, 2001 Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, Hochberg MC, Wells G. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev, Apr 18 (2): 2005 Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster J. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med, 163: 1514–1522, 2003 Pham T, Cornea A, Blick KE, Jenkins A, Scofield RH. Oral glucosamine in doses to treat osteoarthritis worsens insuline resistance. Am J Med Sci, 333: 333–339, 2007 Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev, Apr 19 (2): CD005321, 2006 Divine JG, Zazulak BT, Hewett TE. Viscosupplementation for knee osteoarthritis: a systematic review. Clin Orthop Relat Res, 455: 113–122, 2007 Reichenbach S, Blank S, Rutjes AW, Shang A, King EA, Dieppe PA, Jüni P, Trelle S. Hylan versus hyaluronic acid for osteoarthritis of the knee: a systematic review and meta-analysis. Arthritis Rheum, 57: 1410–1418, 2007 Mazières B, Bard H, Ligier M, Bru I, dÓrsay GG, Le Pen C. Medicoeconomic evaluation of hyaluronic acid for knee osteoarthritis in everyday practice: the MESSAGE study. Joint Bone Spine, 74: 453–460, 2007 van den Bekerom MP, Lamme B, Sermon A, Mulier M. What is the evidence for viscosupplementation in the treatment of patients with hip osteoarthritis? Systematic review of the literature. Arch Orthop Trauma Surg, 815–823, 2007 Spector TD. Bisphosphonates: potential therapeutic agents for disease modification in osteoarthritis. Aging Clin Exp Res, 15: 413–418, 2003 Hayami T, Pickarski M, Wesolowski GA, McLane J, Bone A, Defestano J, Rodan GA, Duong le T. The role of subchondral bone remodelling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transaction model. Arthritis Rheum, 50: 1193–1206, 2004 Carbone LD, Nevitt MC, Wildy K, Barrow KD, Harris F, Felson D, Peterfy C, Visser M, Harris TB, Wang BW, Kritchevsky SB. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum, 50: 3516–3525, 2004 Buckland-Wright JC, Messent EA, Bingham CO 3rd, Ward RJ, Tonkin C. A 2 year longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. Rheumatology (Oxford), 46: 257–264, 2007 Spector TD, Conaghan PG, Buckland-Wright JC, Garnero P, Cline GA, Beary JF, Valent DJ, Meyer JM. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial. Arthitis Res Ther, 7: R625–R633, 2005 Bingham CO 3rd, Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S, Clauw DJ, Spector TD, Pelletier JP, Raynauld JP, Strand V, Simon LS, Meyer JM, Cline GA, Beary JF. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum, 54: 3494–3507, 2006 El Hajjaji H, Williams JM, Devogelaer JP, Lenz ME, Thonar EJ, Manicourt DH. Treatment with calcitonin prevents the net loss of collagen, hyaluronan and proteoglycan aggregates from cartilage in the early stages of canine experimental osteoarthritis. Osteoarthritis Cartilage, 12: 904–911, 2004 Behets C, Williams JM, Chappard D, Devogelaer JP, Manicourt DH. Effects of calcitonin on subchondral bone changes and on osteoarthritic cartilage lesions after acute anterior cruciate ligament deficiency. J Bone Miner Res, 19: 1821–1826, 2004 Sondergaard BC, Wulf H, Henriksen K, Schaller S, Oestergaard S, Qvist P, Tankó LB, Bagger YZ, Christiansen C, Karsdal MA. Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinases expression and activity in articular chondrocytes. Osteoarthritis Cartilage, 14: 759–768, 2006 Karsdal MA, Sumer EU, Wulf H, Madsen SH, Christiansen C, Fosang AJ, Sondergaard BC. Induction of increased cAMP levels in articular chondrocytes blocks matrix metalloproteinase-mediated cartilage degradation, but not aggrecanase-mediated cartilage loss. Arthritis Rheum, 56: 1549–1558, 2007 Karsdal MA, Sondergaard BC, Arnold M, Christiansen C. Calcitonin affects both bone and cartilage: a dual action treatment for osteoarthritis? Ann N Y Acad Sci, 1117: 181–195, 2007 Manicourt DH, Azria M, Mindeholm L, Thonar EJ, Devogelaer JP. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum, 54: 3205–3211, 2006 Kemp G, Crossley KM, Wrigley TV, Metcalf BR, Hinman RS. Reducing joint loading in medial knee osteoarthritis: shoes and canes. Arthritis Rheum, 59: 609–614, 2008 Fransen M, McConnell S, Bell M. Exercise for osteoarthritis of the hip or knee. Cochrane Database Syst Rev 3, CD004376. Review, 2001